A Phase I/II Study to Assess the Safety,Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Patients With Locally Advanced or Metastatic T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Limertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Jiangsu Aosaikang Pharmaceutical
Most Recent Events
- 17 Jan 2025 Results (n=301) presented in an Innovent Biologics, Inc.
- 07 Jun 2022 Results assessing efficacy and safety of ASK120067 in patients with locally advanced or metastatic EGFR T790M mutated non-small cell lung cancer, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 01 Jun 2022 Primary endpoint (Objective response rate) has been met, according to Results published in the Journal of Thoracic Oncology.